Les activités du CHUV
d'immunologie et allergie
Accueil > Research > Vaccine and Immunotherapy Center > Ongoing studies - Etudes en cours


Division of Immunology and Allergy
Vaccine and Immunotherapy Center
1011 Lausanne, Switzerland

Tel.: +41 21 314 1160 / +41 21 314 1163
Fax: +41 21 314 1161

Monday to Friday: 8 am - 6 pm

Now recruiting  

FAQ volunteers

Version française

Ongoing studies




HVTN 704 / HPTN 085 or AMP Study


Design: Multicenter, randomized, controlled, double-blind trial

Status: Study in progress

Length of the study: 21 months


A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men.


70 men and transgender persons who have sex with men, in good health, HIV-uninfected and aged 18-50 years old will be enrolled at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne for 21 months with monthly visits. Participants will receive 10 IV infusions (containing either the antibody or a placebo) and will have follow-up visits including blood sampling.


For further information on this study, please contact us by phone +41 21 314 11 60 / +41 21 314 11 63.